Interstitial pneumonitis following bone marrow transplantation: Pathogenesis and therapeutic considerations
article
High-dose chemo-radiotherapy followed by allogeneic bone marrow transplantation has become standard treatment for a variety of hematological malignancies. Interstitial pneumonitis (IP) is a major complication after bone marrow transplantation, the incidence being approximately 50% (range 20-65%). Cytomegalovirus (CMV) is found in about half of these cases. If no infectious cause can be detected, the interstitial pneumonitis is labeled 'idiopathic'. The occurrence of CMV IP is related to the state of severe immunosuppression in combination with graft-vs-host disease (GvHD) in these patients. The most important factors contributing to idiopathic IP seem to be: chemotherapy, total-body irradiation, agents to prevent GvHD and GvHD itself. For preventing CMV IP hyperimmune globulin seems to be the most promising method at this moment. As long as the etiology of idiopathic IP remains unclear, no measures can be taken to prevent or treat this disease.
Chemicals/CAS: aciclovir, 59277-89-3; azathioprine, 446-86-6; cyclophosphamide, 50-18-0; cyclosporin A, 59865-13-3, 63798-73-2; cytarabine, 147-94-4, 69-74-9; daunorubicin, 12707-28-7, 20830-81-3, 23541-50-6; immunoglobulin G, 97794-27-9; methotrexate, 15475-56-6, 59-05-2, 7413-34-5; prednisone, 53-03-2; trifluridine, 70-00-8; vidarabine, 2006-02-2, 5536-17-4; vincristine, 57-22-7
Chemicals/CAS: aciclovir, 59277-89-3; azathioprine, 446-86-6; cyclophosphamide, 50-18-0; cyclosporin A, 59865-13-3, 63798-73-2; cytarabine, 147-94-4, 69-74-9; daunorubicin, 12707-28-7, 20830-81-3, 23541-50-6; immunoglobulin G, 97794-27-9; methotrexate, 15475-56-6, 59-05-2, 7413-34-5; prednisone, 53-03-2; trifluridine, 70-00-8; vidarabine, 2006-02-2, 5536-17-4; vincristine, 57-22-7
Topics
aciclovirantivirus agentazathioprinecyclophosphamidecyclosporin acytarabinecytomegalovirus vaccinecytostatic agentdaunorubicinimmunoglobulin ginterferonmethotrexateprednisonethymocyte antibodytrifluridinevidarabinevincristineadverse drug reactionblood and hemopoietic systembone marrow transplantationcancer combination chemotherapycytomegalovirusdrug therapygraft versus host reactionhumanimmunosuppressive treatmentinterstitial pneumoniaintoxicationlung toxicitypriority journalradiotherapyrespiratory systemreviewtherapyBone Marrow TransplantationCytomegalovirus InfectionsHumanPostoperative ComplicationsPulmonary Fibrosis
TNO Identifier
229806
ISSN
02775379
Source
European Journal of Cancer and Clinical Oncology, 21(1), pp. 43-51.
Pages
43-51
Files
To receive the publication files, please send an e-mail request to TNO Repository.